Absence of amplification of the FGFR1-gene in human malignant mesothelioma of the pleura: a pilot study

BMC Research Notes

Oliver Schildgen¹  Verena Schildgen¹  Michael Brockmann¹  Erich Stoelben²  Walburga Engel-Riedel²  Frank Beckers²  Till Plönes² 

[1] Institut für Pathologie, Kliniken der Stadt Köln gGmbH, Köln, University Medical Center Witten/Herdecke Merheim, Campus Cologne, Köln, Germany;Department of Thoracic Surgery, University Medical Center Witten/Herdecke, Lung Clinic Merheim, Campus Cologne, Ostmerheimerstrasse 200, 51109 Köln, Germany

关键词: Chemotherapy;    Decortication;    Pleuropneumonectomy;    Asbestos;    Pleural;    Personal medicine;   

Others  :  1130345
DOI  :  10.1186/1756-0500-7-549

 received in 2013-12-30, accepted in 2014-08-14,  发布年份 2014

【 摘 要 】

Background

Mesothelioma (MPM) is a rare malignant disease with a worse outcome. Fibroblast growth factor 1 (FGFR1) may be an interesting target for selective tyrosine kinases inhibitors (TKI) in MPM. The aim of this study was to evaluate the amplification of the FGFR1 gene in patients suffering from MPM.

Findings

We identified nineteen male patients treated in our department between August 2008 and July 2010 matching the inclusion criteria. Mean age was 68 years. Histopathological examination confirmed thirteen patients with epitheloid subtype, five with biphasic and one patient with sarcomatoid. Fluorescence in situ hybridization analysis revealed no polysomy nor an amplification of the FGFR gene copy number in any case.

Conclusion

Regarding that also EGFR amplifications in MPM are absolute rarities, our findings may be a hint that TKI’s will not satisfy the hope for a new era in the treatment of MPM.

【 授权许可】

   
2014 Plönes et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Ploenes T, Osei-Agyemang T, Nestle U, Waller CF, Passlick B: [Malignant pleural mesothelioma]. Dtsch Med Wochenschr 2012, 137(10):481-486.
• [2]Ploenes T, Osei-Agyemang T, Krohn A, Waller CF, Duncker-Rohr V, Elze M, Passlick B: Changes in lung function after surgery for mesothelioma. Asian Cardiovasc Thorac Ann 2013, 21(1):48-55.
• [3]Mir Alireza Hoda KS, Pirker C, Ghanim B, Klikovits T, Laszlo V, Setinek U, Filipits M, Dome B, Hegedues B, Marian B, Grasl-Kraupp B, Klepetko W, Berger W, Grusch M: Targeting the fibroblast growth factor receptor axis in malignant pleural mesothelioma. Cancer Res 2012, Volume 72(Issue 8):ᅟ. Supplement 1, Abstract nr 1067
• [4]Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, Schöttle J, Leenders F, Gabler F, Dabow I, Querings S, Heukamp LC, Balke-Want H, Ansén S, Rauh D, Baessmann I, Altmüller J, Wainer Z, Conron M, Wright G, Russell P, et al.: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010, 2(62):62ra93.
• [5]Schildgen V, Pabst O, Tillmann RL, Lusebrink J, Schildgen O, Ludwig C, Brockmann M, Stoelben E: Low frequency of EGFR mutations in pleural mesothelioma patients, Cologne, Germany. Diagn Mol Pathol 2014, ᅟ:ᅟ. epublished ahead of print
• [6]Okuda K, Sasaki H, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y: Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma. J Cancer Res Clin Oncol 2008, 134(10):1105-1111.
• [7]Rena O, Boldorini LR, Gaudino E, Casadio C: Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations. J Surg Oncol 2011, 104(6):701-705.